Shares of vaccine-developer HilleVax Inc (NASDAQ:HLVX) are down on Monday on a session volume of over 7 million as per data from Benzinga Pro.
Monday, the company released topline data results from the NEST-IN1 Phase 2b randomized, double-blind, placebo-controlled trial of the efficacy, safety, and immunogenicity of HIL-214 in infants approximately five months of age at the time of initial vaccination.
HIL-214 is the company’s investigational virus-like particle (VLP) based vaccine to prevent moderate-to-severe norovirus-related acute gastroenteritis.
Norovirus, also called the “winter vomiting bug,” is a stomach bug that causes ...